Jazz Pharmaceuticals: FDA accepts sNDA for Zepzelca/ Atezolizumab combo

Jazz Pharmaceuticals (JAZZ) announced the U.S. FDA has accepted the supplemental New Drug Application for Zepzelca in combination with Atezolizumab as a first-line maintenance treatment for people with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin, and etoposide for Priority Review, with a Prescription Drug User Fee Act action date of October 7, 2025.